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osmolality coupled to the large fraction of cardiac output 
that constitutes the splanchnic-hepatic circulation min- 
imizes shifts in external osmotic pressure, aside from 
those arising from pathological conditions. It also seems 
that any osmotic imbalance arising from cell metabolism 
or transport would be limited to specific cells, given the 
heterogeneity of metabolic functions in the hepatic 
lobule. Considering the large degree of intercellular 
communication between hepatocytes, presumably by 
means of gap junctions, it is questionable whether such 
osmotic imbalances could be sustained long enough to 
effect changes in protein synthesis. Second, extrapo- 
lation of the authors’ linear plots of protein synthesis vs. 
time did not intersect the origin; instead they crossed the 
x-axis at 6 to 7 min. This could reflect diffusion delays. 
However, it also suggests that activation of a secondary 
cellular mechanism affects protein synthesis, other than 
change in cell volume, which occurs rapidly in isolated 
rat hepatocytes (2). It will be important to consider 
whether changes in activity or concentration of ionic or 
organic mediators affect protein synthesis, in addition to 
changes in water volume per se. 
In summary, this paper presents new and exciting 
results showing that changes in hepatocyte hydration 
affect protein synthesis. This, along with other studies 
(31, suggests that changes in hepatocyte volume pro- 
foundly alter macromolecular synthesis and degra- 
dation. Nevertheless, a crucial question remains to be 
answered: is this phenomenon of importance in normal 
liver function and pathophysiology, or does it result 
from experimental conditions triggering highly con- 
served, vestigial adaptations by cells to survive the dilute 
milieu of the Precambrian environment (4)? Regardless 
of the answer to this question, readers and investigators 
must be aware that, although this problem may be new 
to hepatologists, these hepatologists are sailing into 
well-charted waters. There is a rich history to the study 
of the molecular organization of cells, state of cellular 
water and effects that changes of organization and 
hydration have on cellular metabolism (5-7). This field 
has been rather controversial; notwithstanding, one 
thing seems quite clear, as aptly stated by Clegg (7): 
“Although dimly perceived at present, it appears that 
living cells exhibit an organization far greater than the 
current teachings of cell biology reveal.” 
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ABSTRACT 
We have previously reported data from clinical and 
laboratory animal observations which suggest that 
organ tolerance after transplantation depends on a 
state of balanced lymphodendritic cell chimerism be- 
tween the host and donor graft. We have sought further 
evidence to support this hypothesis by investigating 
HLA-mismatched liver allograft recipients. 
Nine of nine female recipients of livers from male 
donors had chimerism in their allografts and extra- 
hepatic tissues, according to in-situ hybridisation and 
molecular techniques 10 to 19 years post-transplan- 
tation. In 8 women with good graft function, evidence 
of the Y chromosome was found in the blood (6/8), skin 
(8/8), and lymph nodes (7/8). A ninth patient whose 
transplant failed after 12 years from recurrent chronic 
viral hepatitis had chimerism in her lymph nodes, skin, 
jejunum, and aorta at the time of retransplantation. 
Although cell migration is thought to take place after 
all types of transplantation, the large population of 
migratory cells in, and the extent of their seeding from, 
hepatic grafts may explain the privileged toleroge- 
nicity of the liver compared with other organs. 
COMMENTS 
Donor-specific immune tolerance has been a per- 
sistent and elusive goal in clinical transplantation and 
thus a focus of intense immunological research since its 
recognition nearly 50 yr ago. Current immunosup- 
pressive regimens, though clearly effective with the 
introduction of potent medications such as cyclosporin A 
and FK-506, suffer from their nonspecific down-regu- 
lation of immune surveillance and substantial side-effect 
profiles. The promise of therapies capable of selectively 
eliminating host immune responses to the allograft 
while allowing a normal immune barrier to potential 
infectious agents therefore remains attractive. 
Transplantation of allogeneic livers has been accom- 
panied by several clinical observations with regard to the 
recipient immune system (1). The incidence of hyper- 
acute rejection caused by preformed cytolytic antibodies 
is dramatically reduced in liver allografts compared with 
allogeneic kidney or heart transplants. More important, 
after liver transplantation skin and solid organs from 
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the same donor are not rejected, though allografts from 
an unrelated third party fail in the absence of immuno- 
suppressive medication. Liver transplantation is also 
associated with reduced incidence of graft-vs.-host reac- 
tions despite the large numbers of lymphocytes trans- 
ferred with the liver allograft. Each of these features 
indicates that the transplanted liver interacts with the 
host immune system in some manner so as to create a 
more tolerant environment. A variety of mechanisms 
have been advocated to explain these observations, 
including induction of peripheral tolerance by secretion 
of soluble major histocompatibility complex class I 
molecules from the allograft (21, altered secretory 
patterns by the host antigen-presenting cells (3), clonal 
deletion of reactive lymphocytes by the allograft (4) and 
development of suppressor cells derived from the host 
hematopoietic cell line in response to establishment of 
stable systemic mixed chimerism after transplantation 
(5). The article under review seeks to bolster last 
hypothesis by providing evidence of stable mixed chi- 
merism in the peripheral tissues of long-term liver 
allograft recipients. 
Indirect evidence of systemic mixed chimerism after 
liver transplantation has mounted over the last decade. 
The allograft is invaded by host mononuclear cells, 
which replace the Kupffer cells of donor origin. Thus in 
the vascular compartment of the allograft mononuclear 
cells of the host coexist with endothelial cells and 
hepatocytes of donor origin. Ramsey et al. (6) reported in 
1984 results from 40 patients who received ABO- 
mismatched liver allografts. Twenty-eight percent of 
evaluated patients demonstrated antibodies to recipient 
A or B antigens 8 to 16 days after transplantation, 
persisted for 2 to 4 wk and resulted in clinically evident 
hemolysis in 5 of these patients. The time course and the 
predominance of IgG-type antibodies were consistent 
with a secondary immune response derived from primed 
donor lymphocytes transferred in the lymphatics and 
lymph nodes of the allograft. More recently, Selby et al. 
(7) described a patient with type Tv glycogen storage 
disease who had resolution of extrahepatic amylopectin 
deposits after liver transplantation. Because the enzy- 
matic defect in this condition is universal, cells of donor 
origin without the defective enzyme must have migrated 
to peripheral tissues, where the deposits were degraded 
over time. The resistance of solid organ allografts to 
rejection appears to correlate with the volume of 
passenger lymphoid cells able to enter circulation. In a 
series of studies reviewed by Russell (8), the size of the 
transplanted tissue and access to the vascular com- 
partment were directly related to transplant tolerance. 
Although no mechanistic role can be assigned to the 
donor immune cells in these studies, the results are 
consistent with the hypothesis that passenger immune 
cells modulate organ acceptance by the host. 
The article under comment presents evidence of 
systemic migration by donor cells into the peripheral 
tissues, where they are maintained over long periods of 
time. Nine female recipients of ABO-matched, HLA- 
mismatched liver allografts from male donors were 
evaluated 10 to 19 yr after transplantation for evidence 
of systemic mixed chimerism. Eight patients were 
receiving immunosuppressive medication at the time of 
the study (five were receiving prednisone and azathio- 
prine; three were receiving cyclosporine and prednisone) 
and had normal liver function. One patient, evaluated at  
the time of repeat transplantation necessitated by 
recurrent viral hepatitis, was reported to have been off 
cyclosporine for 7 yr without evidence clinical or histo- 
logical of rejection. No information on prior episodes of 
acute rejection or specific dosing regimens was provided 
for the other patients. The patients underwent biopsies 
of skin, inguinal lymph nodes and liver allograft as well 
as whole blood sampling. The patient who underwent 
repeat transplantation also had biopsy specimens taken 
from jejunum and aorta at the time of surgery. These 
tissue samples were examined with in situ hybridization 
with a probe specific for satellite regions associated with 
the Y chromosome. The authors found reactive cells, 
resembling small lymphocytes, in the subepidermal 
stroma, perivascular sheaths and the pericapsular 
region of lymph nodes. In addition, specimens were 
examined by polymerase chain reaction using primers 
designed to amplify the satellite regions of the Y 
chromosome. All patients examined had evidence of 
chimerism in at least two sites on in situ hybridization 
or PCR. Cells of “male” origin were also detected in the 
aortic and jejunal specimens. Finally, using peripheral 
blood lymphocytes from four of these patients, the 
authors demonstrated normal proliferative responses by 
host lymphocytes on stimulation by mitogens or irra- 
diated lymphocytes from an unrelated third party. 
Unfortunately, because no lymphoid tissue was pre- 
served from the donors at the time of transplantation, 
host immune responses to donor-specific lymphocytes 
could not be evaluated. 
The presence of donor mononuclear cells in the 
peripheral tissues of transplant recipients has been 
described previously in patients with severe graft-vs.- 
host disease after liver transplantation. Roberts et al. (9) 
used restriction-fragment-length polymorphisms to 
identify the donor as the source of infiltrating mononu- 
clear cells in kidney, spleen and pancreatic specimens 
obtained at autopsy. A limitation of the Starzl study is 
its failure to definitively identify the “male” cells as 
being of donor origin. Adams et al. (10) demonstrated 
prolonged circulation of donor lymphocytes in surgical 
patients, including two liver transplant recipients, who 
received large-volume blood transfusions. In addition, 
graft-vs.-host disease is a recognized, albeit rare, com- 
plication of transfusions during coronary artery bypass 
surgery. Circulating lymphocytes could have entered the 
peripheral tissues at this time. However, the large 
volume of passenger lymphocytes transferred with the 
allograft would favor this as the source for these cells. 
Despite this limitation, the article raises the role of 
mixed chimerism in the immune tolerance of the liver 
allograft. Ildstad et al. (5) have shown in experimental 
murine models of mixed chimerism that even small 
numbers of donor lymphocytes can maintain transplant 
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tolerance. Similarly, the concept of microchimerism has 
been advocated as a mechanism maintaining tolerance 
in settings where donor mononuclear cells could not be 
identified. The application of sensitive techniques to 
identify these cells in biopsy specimens will now allow 
this hypothesis to be evaluated. 
The importance of systemic mixed chimerism in 
maintaining long-term allograft tolerance is not ad- 
dressed by Starzl’s study. Eight of the nine patients were 
still taking immunosuppressive medications at the time 
of their biopsies. No information is provided on the 
extent of the chimerism observed in the biopsies; nor is 
it possible to correlate the degree of chimerism with the 
clinical course of these patients. Interestingly, the 
authors report seven long-term liver transplant recip- 
ients who are apparently off all medications without 
evidence of rejection, though details are not provided. 
This highlights the need for future studies detailing the 
clinical significance of this observation and identifies 
patients who may provide important information on 
long-term tolerance in human subjects. Studying the 
clinical effects of this mixed chimerism will not be an 
easy task, particularly because liver-transplant recip- 
ients secrete large amounts of soluble class I human 
leukocyte antigen into circulation and have often re- 
ceived multiple blood transfusions before transplan- 
tation. Both occurrences have been demonstrated to 
induce loss of T-cell responsiveness in animal models 
and human patients awaiting transplantation (2, 11). 
Nonetheless, the presence and extent of systemic mixed 
tolerance may serve as a marker of specific tolerance. If 
so, it may provide a means to rationally adjust the degree 
of nonspecific immunosuppression these patients need 
to endure to  maintain graft viability while minimizing 
the risk of infectious complications. Again, careful 
examination for the presence and extent of systemic 
chimerism, combined with direct evaluation of specific 
host-donor immune responses, will be necessary. Should 
this chimerism accurately reflect the degree of specific 
tolerance, additional studies may be directed toward 
therapies that ensure its development in all patients 
even as the underlying mechanisms continue to be 
explored. The detection of systemic mixed chimerism by 
this study should provide a stimulus for future study 
into this phenomenon and its clinical importance. 
THOMAS JUDGE, M.D. 
University of Michigan 
Ann Arbor, Michigan 481 05 
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DRUG TARGETING TO THE LIVER WITH BILE 
ACIDS: THE “TROJAN HORSE” RESURRECTED? 
Kramer W, Wess G, Schubert G, Bickel M, Girbig F, 
Gutjahr U, Kowalewski S, et al. Liver-specific drug 




Bile acids are selectively taken up from portal blood 
into the liver by specific transport systems in the 
hepatocyte plasma membrane. Therefore, studies 
were performed to evaluate the potential of bile acids 
as shuttles to deliver drugs specifically to the liver. 
The alkylating cytostatic drug chlorambucil and the 
fluorescent prolyl-4-hydroxylase inhibitor 4-nitroben- 
zo - 2 - oxa - 1,3-diazol-~-Ala-Phe-5-oxaproline-Gly were 
covalently linked via an amide bond to 7q12q- 
dihydroxy-3~-(w-aminoalkoxy)-5-~-cholan-24-oic acid. 
The chlorambucil-bile acid conjugates S 2521, S 2539, 
S 2567, and S 2576 inhibited Na+-dependent I3Hltau- 
rocholate uptake in a concentration-dependent 
manner both into isolated rat hepatocytes and rabbit 
ileal brush border membrane vesicles, whereas the 
parent drug chlorambucil showed no significant inhib- 
itory effect. The chlorambucil-bile acid conjugates 
were able to prevent photoaffinity labeling of bile acid 
binding proteins in rat hepatocytes by the photolabile 
[3H]7,7-azo derivative of taurocholic acid indicating 
their bile acid character. The chlorambucil-bile acid 
conjugate S 2577 was able to alkylate proteins demon- 
strating the drug character conserved in the hybrid- 
molecules. 
Liver perfusion experiments revealed a secretion 
profile of the chlorambucil-bile acid conjugate S 2576 
into bile very similar to taurocholate compared to 
chlorambucil which is predominantly excreted by 
the kidney. 4-Nitrobenzo-2-oxa-1,3-diazol-~-Ala-Phe-5- 
oxaproline-Gly-t-butylester ( S  4404), a fluorescent 
peptide inhibitor of prolyl-4-hydroxylase, was not 
transported in intact form from portal blood into bile 
in contrast to its bile acid conjugate S 3744; about 25% 
of the peptide-bile acid conjugate S 3744 was secreted 
in intact form into bile within 40 min compared with 
less than 4% of the parent oxaprolylpeptide S 4404. 
